Flebaven® (Flebaven®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspfilm coated tablets
Composition:

For 1 tablet

Core:

Purified micronized flavonoid fraction, substance - granules 613.00 mg

[Active substance of substance - granules:

Purified Micronized Flavonoid Fraction1 500.00 mg

Auxiliary substances of substance - granules:

Cellulose microcrystalline 82.00 mg, povidone K-30 31.00 mg]

Excipients:

Carboxymethyl starch sodium 27.00 mg, talc 6.00 mg, magnesium stearate 4.00 mg

Film sheath:

Fold orange 03N325992 18.00 mg

1 The purified micronized flavonoid fraction contains 90% (450 mg) of diosmin and 10% (50 mg) of other flavonoids in terms of hesperidin.

2 Fold orange 03N32599 contains: Hypromellose 71.714%, titanium dioxide (E171) 15.936%, talc 6.972%, propylene glycol 4.980%, iron dye oxide yellow (E172) 0.332%, iron dye oxide red (E172) 0.066%.

Description:

The capsule-shaped, biconvex tablets covered with a film cover of light orange-pink color.

Type of tablets on the fracture: a rough mass from yellow to brownish-yellow with a film coating of light orange-pink color.

Pharmacotherapeutic group:Venotonizing and venoprotective agent
ATX: & nbsp
  • Diosmin in combination with other drugs
    • Pharmacodynamics:

    Combination hesperidin + diosmin has venotonic and angionotectic properties.Reduces the extensibility of veins and venous congestion, in microcirculation - reduces the permeability of capillaries and increases their resistance, improves the indices of venous hemodynamics. Influences on the following venous plethysmographic parameters: venous capacity, venous dilatability, time of venous emptying. The optimum effect is achieved when taking 2 tablets. Combination hesperidin + diosmin increases venous tone by reducing the time of venous emptying. In patients with signs of severe disturbance of microcirculation, there is an increase in capillary resistance.

    Combination hesperidin + diosmin effective in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.

    Pharmacokinetics:

    The preparation Flebaven® is mainly excreted through the intestine. On the average, about 14% of the dose of the drug is excreted by the kidneys.

    The half-life is 11 hours.

    The drug is subject to active metabolism, which is confirmed by the presence of phenolic acids in the urine.

    Indications:

    Therapy of symptoms of venous-lymphatic insufficiency:

    - feeling of heaviness in the legs;

    - pain;

    - "fatigue" of the feet.

    Symptomatic therapy of acute hemorrhoids.

    Contraindications:

    - Hypersensitivity to the active ingredients or to the auxiliary substances included in the preparation.

    - It is not recommended to take the drug during breastfeeding.

    Pregnancy and lactation:

    Pregnancy

    Experiments on animals did not reveal teratogenic effects.

    To date, there have been no reports of any side effects when the drug is used by pregnant women.

    Breastfeeding period

    Because of the lack of data on excretion of the drug with breast milk, women during breast-feeding are not recommended taking the drug.

    Dosing and Administration:

    Inside.

    The recommended dose for venous-lymphatic insufficiency is 2 tablets per day:

    1 tablet - in the middle of the day and 1 tablet - in the evening, during a meal. The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

    The recommended dose for acute hemorrhoids is 6 tablets per day: 3 tablets in the morning and 3 tablets in the evening for 4 days, then 4 tablets per day: 2 tablets in the morning and 2 tablets in the evening for the next 3 days .
    Side effects:

    Classification of the incidence of side effects recommended by the World Health Organization (WHO):

    very often ≥1 / 10

    often from ≥1 / 100 to <1/10

    infrequently from ≥1 / 1000 to <1/100

    rarely from ≥1 / 10000 to <1/1000

    very rarely <1/10000

    the frequency of the unknown can not be estimated from the available data.

    From the central nervous system:

    rarely: dizziness, headache, general malaise.

    From the digestive system:

    often: diarrhea, indigestion, nausea, vomiting, infrequently: colitis.

    frequency unknown: abdominal pain.

    From the skin:

    rarely: skin rash, itching, hives.

    frequency unknown: isolated edema of the face, lips, eyelids. In exceptional cases angioedema.

    INFORM THE DOCTOR ON THE APPEARANCE OF YOU ANYONE, INCLUDING NOT ALLOWED IN THESE INSTRUCTIONS, ADVERSE REACTIONS AND SENSATIONS; AND ALSO ABOUT CHANGING LABORATORY INDICES AT THE BACKGROUND OF THERAPY.

    Overdose:

    Cases of overdose are not described.

    In case of an overdose of Flebaven®, seek medical advice immediately.

    Interaction:

    Not noted.

    Should inform your doctor about any decisions you Medicinal prep TAX.

    Special instructions:

    - Before you start taking the drug Flebaven®, it is recommended to consult a doctor.

    - With exacerbation of hemorrhoids, the use of the Flebaven® preparation does not replace the specific treatment of other anal disorders. Duration of treatment should not exceed the time specified in the section "Method of administration and dose". In the event that the symptoms do not disappear after the recommended course of therapy, you should undergo an examination with a proctologist who will choose further therapy.

    - In the presence of violations of venous circulation, the maximum effect of treatment is provided by combining therapy with a healthy (balanced) way of life: it is advisable to avoid long exposure to the sun, prolonged stay on legs, and it is also recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings, helps improve blood circulation.

    - Seek medical attention immediately if your condition worsens or if there is no improvement in the treatment process.

    Effect on the ability to drive transp. cf. and fur:Does not affect.
    Form release / dosage:

    Tablets, film-coated, 500 mg.

    Packaging:

    For 16 tablets in a planar cell pack of PVC film and aluminum foil.

    2, 4 or 6 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C, in the original packaging.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use the drug after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-003371
    Date of registration:17.12.2015
    Expiration Date:17.12.2020
    The owner of the registration certificate:KRKA-RUS, LLC KRKA-RUS, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp21.03.2017
    Illustrated instructions
      Instructions
      Up